With Added Organic Compound Patents (Class 424/629)
-
Patent number: 9492374Abstract: There is provided pharmaceutical compositions suitable for the treatment of infected ulcers in mammals, such as diabetes related ulcers and varicose ulcers. Said compositions comprise vancomycin, gentamicin, amikacin, fluconazole, ciprofloxacin and metronidazole or its corresponding salts and an hypertonic amount of sodium chloride in a suitable polar and aprotic or protic acidic as pharmaceutical carrier. There is further disclosed a methods for treating ulcers in mammals using the disclosed compositions.Type: GrantFiled: March 25, 2015Date of Patent: November 15, 2016Inventor: Jose Rafael Salinas Andrade
-
Patent number: 9028878Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.Type: GrantFiled: August 3, 2012Date of Patent: May 12, 2015Assignee: Microbion CorporationInventor: Brett Hugh James Baker
-
Publication number: 20150086643Abstract: A traditional Chinese medicine compound antitumor nano preparation, comprising the following components by weight percentage: 28%-32% of solid lipid nanoparticles containing volatile oil of frankincense and myrrh, 61%-65% of nano realgar carrying microcapsule, 0.8%-1.3% of bezoar micro-powder and 4%-6% of musk micro-powder. Use of the above traditional Chinese medicine compound antitumor nano preparation for preparing antitumor drugs. The traditional Chinese medicine compound antitumor nano preparation of the present invention can remarkably improve bioavailability of every component in the traditional Chinese medicine compound; at the same time, it can achieve better curative effect with reduced dosage.Type: ApplicationFiled: February 13, 2014Publication date: March 26, 2015Inventors: Nianping Feng, Feng Shi, Ying Liu, Jihui Zhao, Yongtai Zhang
-
Patent number: 8974915Abstract: PU/ZnO nanocomposites are provided wherein the addition of less than 1 vol % 33 nm ZnO nanoparticles into a PU matrix effect a decrease in the Young's Modulus and storage modulus of the polymer, while simultaneously effecting an increase glass transition temperature of the polymer. Detailed experiments are described (e.g., FTIR, DMTA, FESEM and AFM) that suggest that the reaction between hydroxyl groups of the ZnO nanoparticles and isocyanate groups of the polyurethane prepolymer disrupts the self-assembly of the phase separation in PU. Phase separation is responsible for the good mechanical properties of PU. Further, detailed experiments suggest that the increase of the glass transition temperature results from the crosslinking effect of the ZnO nanoparticles.Type: GrantFiled: March 16, 2005Date of Patent: March 10, 2015Assignee: Rensselaer Polytechnic InstituteInventors: Junrong Zheng, Rahmi Ozisik, Richard W. Siegel
-
Publication number: 20140227221Abstract: Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents.Type: ApplicationFiled: December 4, 2013Publication date: August 14, 2014Applicant: Prolexys Pharmaceuticals, Inc.Inventors: Paul B. Robbins, Sudhir R. Sahasrabudhe
-
Patent number: 8389021Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.Type: GrantFiled: February 3, 2010Date of Patent: March 5, 2013Assignee: Microbion CorporationInventor: Brett Hugh James Baker
-
Publication number: 20120195974Abstract: The invention disclosed in this document concerns controlling mealybugs.Type: ApplicationFiled: January 27, 2012Publication date: August 2, 2012Applicant: DOW AGROSCIENCES LLCInventors: Mayank Yadav, Suresh Ramachandran, Sanjoy Kundu
-
Publication number: 20120070511Abstract: Compositions which modulate mitochondrial functions treat diseases associated with cells that are hyperactively using their endoplasmic reticulum. Screening assays identify agents which modulate mitochondrial functions.Type: ApplicationFiled: September 21, 2011Publication date: March 22, 2012Applicant: UNIVERSITY OF MIAMIInventors: Theodore Lampidis, Metin Kurtoglu
-
Publication number: 20110123486Abstract: Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents.Type: ApplicationFiled: June 25, 2008Publication date: May 26, 2011Applicant: Prolexys Pharmaceuticals, Inc.Inventors: Paul B Robbins, Sudhir R. Sahasrabudhe
-
Publication number: 20110110885Abstract: Methods for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside or an anthocyanin are provided. More particularly, a method for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside having the structure of formula (IV): Formula (IV) wherein R is selected from H or CH3 or an anthocyanin selected from cyanidin 3-glucoside, delphinidin 3-glucoside, or combinations thereof, or an enantiomer, optical isomer, diastereomer, N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof is provided. Also provided are compounds according to Formulas I-IV, pharmaceutical compositions, unit dosage forms, and food or feed supplements containing such compounds.Type: ApplicationFiled: July 31, 2007Publication date: May 12, 2011Inventors: Jeanine D'Armiento, Kurt Reynertson, Edward Kennelly, Alison Wallace
-
Publication number: 20100316566Abstract: The present invention concerns methods and compositions related to a chelator and a HHRT ligand. In specific embodiments of the invention the chelator is conjugated to the HHRT ligand. In another specific embodiment of the invention, the chelator is chelated to a metal. In a particular embodiment of the invention, there is a metal species that is chelated to a chelator, which is then directly or indirectly conjugated to a HHRT ligand. In some embodiments, the composition further comprises a therapeutic agent. In particular cases, the compositions are employed for cancer diagnosis and/or therapy.Type: ApplicationFiled: February 27, 2009Publication date: December 16, 2010Applicant: RADIOMEDIX INC.Inventors: Jennifer Sims-Mourtada, Ali Azhdarinia, Izabela Tworowska, Hitomi Saso
-
Patent number: 7619000Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.Type: GrantFiled: February 6, 2006Date of Patent: November 17, 2009Assignees: The Texas A&M University System, Board of Regents, The University of Texas SystemInventors: Ralph A. Zingaro, Emil J. Freireich, Hatice Duzkale, Hagop Kantarjian, Srdan Verstovsek, Merida Sotelo-Lerma
-
Patent number: 7563461Abstract: The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts to prevent the irritation of skin or mucous membranes that may be caused by therapeutic agents, by personal hygiene products, or by various physical, chemical, mechanical, or biological irritants, including infectious agents.Type: GrantFiled: June 2, 2005Date of Patent: July 21, 2009Assignee: The Trustees of Columbia University in the City of New YorkInventors: Shanta M. Modak, Trupti Gaonkar, Milind Shintre, Lauserpina Caraos, Ingrid Geraldo
-
Patent number: 7205001Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.Type: GrantFiled: November 3, 2003Date of Patent: April 17, 2007Assignee: Polarx Biopharmaceuticals, Inc.Inventors: Ralph M. Ellison, Fred H. Marmelstein
-
Patent number: 7179493Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.Type: GrantFiled: August 28, 2003Date of Patent: February 20, 2007Assignee: PolaRx Biopharmaceuticals, Inc.Inventors: Ralph M. Ellison, Fred H. Marmelstein
-
Patent number: 7163703Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.Type: GrantFiled: August 14, 2003Date of Patent: January 16, 2007Assignee: PolaRx Biopharmaceuticals, Inc.Inventors: Ralph M. Ellison, Fred H. Mermelstein
-
Patent number: 7060656Abstract: An antibacterial rockwool growth medium for hydroponics is used for hydroponic growth of rice, flowers and ornamental plants, fruitage, etc. The medium includes a rockwool base used as a culture medium for hydroponics, and an inorganic antibacterial agent is dispersed substantially uniformly onto an overall surface of the rockwool base or a part of the surface of the rockwool base.Type: GrantFiled: December 17, 2003Date of Patent: June 13, 2006Assignee: Akechi Ceramics Kabushiki KaishaInventors: Yoshinari Kato, Satoshi Kameshima
-
Patent number: 6995188Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.Type: GrantFiled: January 13, 2005Date of Patent: February 7, 2006Assignees: Board of Regents, The University of Texas System, The Texas A&M University SystemInventors: Ralph A. Zingaro, Emil J. Freireich, Hatice Duzkale, Hagop Kantarjian, Srdan Verstovsek, Merida Sotelo-Lerma
-
Patent number: 6939566Abstract: Microbicidal formulations are described which are preferably ecologically friendly and non-toxic to mammals, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having the formula R-M, wherein R is at least one organic chelating moiety and M is at least one metal ion which is microbicidal to at least one microorganism. These complexes can disrupt microorganism activities by penetrating the natural protecting bio-films of such microorganisms through the reaction of the R-group with the organic constituents of these microorganisms while releasing M into their intra-cellular media. Thus, this process exhibits its biocidal activities from the inside-out, contrary to other methods which rely on damaging the protective biofilms.Type: GrantFiled: January 17, 2001Date of Patent: September 6, 2005Inventors: Kareem I. Batarseh, Marwan Al-Kayed
-
Patent number: 6911471Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.Type: GrantFiled: January 7, 2003Date of Patent: June 28, 2005Assignees: The Texas A&M University System, Board of Regents, The University of Texas SystemInventors: Ralph A. Zingaro, Emil J. Freireich, Hatice Duzkale, Hagop Kantarjian, Srdan Verstovsek, Merida Sotelo-Lerma
-
Patent number: 6875451Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.Type: GrantFiled: October 15, 1998Date of Patent: April 5, 2005Assignee: PolaRx Biopharmaceuticals Inc.Inventors: Ralph M. Ellison, Fred H. Mermelstein
-
Patent number: 6861075Abstract: A storage-stable biocidal aerated gel composition comprises from 30 to 97% by weight of water, from 0.2 to 5% by weight of a gelling agent selected from xanthan gum, sodium alginate and neutralised carboxyvinyl polymer from 2 to 5% by weight of a fine particulate, hydrophobic silicone-treated silica having a surface area of from 80 to 300 m2/g and from 0.004 to 20% by weight of a biocide which said composition is in the form of fine particles of an aqueous gel containing the water, gelling agent and the biocide, the surfaces of which fine particles are coated with a coating of the finely particulate hydrophobic silica. The biocidal aerated gel composition can be used to control pests using one or more appropriate biocides in the composition.Type: GrantFiled: April 6, 2001Date of Patent: March 1, 2005Assignee: Sorex LimitedInventor: Roland S. Twydell
-
Patent number: 6764692Abstract: A method of treating laminitis in a horse is disclosed, comprising administering to the horse a naturally chelated trace mineral composition; promoting healthy skin, hair and hoof tissue. A method of reducing dietary intake is also disclosed, comprising administering to a horse in need thereof, effective amounts of a naturally chelated trace mineral composition. A method of preparing the chelated trace mineral composition from ocean seabed rock is further disclosed, as well as the chelated trace mineral composition.Type: GrantFiled: August 27, 2002Date of Patent: July 20, 2004Inventor: Carlos Cortelezzi
-
Patent number: 6733798Abstract: The present invention includes a cranberry seed oil, a cranberry flour and a method for making cranberry seed oil and flour. The cranberry seed oil comprises beta sitosterol and phosphatidylcholine.Type: GrantFiled: May 20, 2002Date of Patent: May 11, 2004Inventors: Tim Heeg, Bernard G. Lager, II
-
Publication number: 20040028750Abstract: The present invention relates to arsenic sulfide compounds. The present invention also relates to pharmaceutical compositions useful for treating cancer, such as leukemia or lymphoma, which comprises an arsenic sulfide compound. The present invention further relates to methods for treating cancer, such as leukemia or lymphoma, using an arsenic sulfide compound. Finally, the present invention relates to processes for producing arsenic disulfide (As4S4).Type: ApplicationFiled: August 7, 2003Publication date: February 12, 2004Applicant: Cell Therapeutics, Inc.Inventor: Daopei Lu
-
Patent number: 6630172Abstract: Disinfectant formulations are described which are preferably ecologically friendly and non-toxic to mammals and plants, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having at least one metal ion which is microbicidal to at least one microorganism and potassium sodium tartrate in some form. When potassium sodium tartrate is used with these metal ions, it enhances the complex-forming properties of such metal complexes while concurrently increases their efficacy and potency at the same level of metal ion concentrations. These microbicidal formulations can be diluted in suitable proportions into aqueous systems to produce the desired dosages for each individual case, depending on the level and the severity of the contamination. The microbicidal formulations can be applied by conventional methods, e.g., spraying, soaking, fogging, impregnation, and the like.Type: GrantFiled: January 22, 2001Date of Patent: October 7, 2003Inventor: Kareem I. Batarseh
-
Patent number: 6521265Abstract: A method of arresting the flow of blood and other protein containing body fluids flowing from an open wound and for promoting wound healing. In the method, a substantially anhydrous compound of a salt ferrate is provided for a unique use which, when hydrated after mixing with a victim's own blood or other aqueous media, produces Fe+++ thereby promoting clotting when applied in a paste form to the wound for a time sufficient to arrest substantial further blood and other body fluid flow from the wound. The compound is formed of a ferrate (VI) salt taken from the group consisting of H, Li, Na, K, Rb, Cs and Fr. However, to decrease or eliminate stinging sensation, the compound may be formed having a ferrate (VI) salt taken from the group consisting of Be, Mg, Ca, Sr, Ba, Ra, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn, Hf, Ta, W, Re, Os, Ir, Pt, Au, Hg, TI, Pb, Bi, Al, As, NH4 and N(C4H9)4.Type: GrantFiled: June 13, 2000Date of Patent: February 18, 2003Assignee: Biolife, L.L.C.Inventor: James A. Patterson
-
Patent number: 6413551Abstract: A termiticide which comprises at least one compound which in the presence of a termite produces a termiticidally effective amount of hydrogen sulfide.Type: GrantFiled: January 26, 2001Date of Patent: July 2, 2002Inventor: David William Holloway
-
Publication number: 20020054919Abstract: Novel compositions and methods for reducing odor. The composition comprises at least one synthetic zeolite, at least one acid and at least one substance selected from a metal oxide, metal, or salt of a metal or metal oxide. A wide range of odors, including ammonia and sulfurous odors, may be controlled by contacting an effective amount of the above composition with the article, substance or environment that emits the undesired odor. The composition may also be incorporated into other substances for odor reduction or control to form odor-controlled articles.Type: ApplicationFiled: September 6, 2001Publication date: May 9, 2002Inventors: Mark A. Hochwalt, Michael L. Trehy
-
Patent number: 6242009Abstract: Microbicidal formulations are described which are preferably ecologically friendly and non-toxic to mammals, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having the formula R-M, wherein R is at least one organic chelating moiety and M is at least one metal ion which is microbicidal to at least one microorganism. These complexes can disrupt microorganism activities by penetrating the natural protecting bio-films of such microorganisms through the reaction of the R-group with the organic constituents of these microorganisms while releasing M into their intra-cellular media. Thus, this process exhibits its biocidal activities from the inside-out, contrary to other methods which rely on damaging the protective biofilms.Type: GrantFiled: April 20, 1999Date of Patent: June 5, 2001Inventors: Kareem I. Batarseh, Marwan Al-Kayed
-
Patent number: 5985335Abstract: The invention relates to an agent for the prophylaxis and/or therapy of conditions associated with a disorder of bone formation. It contains alkali metal citrates and/or alkali metal lactates and/or alkali metal malates, optionally together with one or more active substances selected from vitamin K, calcium salts and vitamin D. The agent preferably contains potassium citrates and/or sodium citrates or potassium lactates and/or sodium lactates and serves for the prophylaxis and/or therapy of osteoclasis, in particular osteoporosis or osteomalacia.Type: GrantFiled: November 28, 1997Date of Patent: November 16, 1999Assignee: Orthomol Pharmazeutische Vertriebs GmbHInventor: Hans Dietl
-
Patent number: 5709890Abstract: An insecticide composition is enhanced from the standpoint of its ability to be absorbed by insects, such as red fire ants, particularly dithiophosphate ester pesticides by the addition of a small amount of a water soluble non-aromatic polyorganic acid or salt form thereof such as polyaspartic acid, particularly preferred with a molecular weight in the range of about 3000 to 40,000.Type: GrantFiled: March 20, 1997Date of Patent: January 20, 1998Assignee: Donlar CorporationInventor: J. Larry Sanders
-
Patent number: 5198230Abstract: This invention provides a recipe for making a detoxification medicine named DTS (Deities) for curing drug addiction. This DTS (Deities) medicine comprises no narcotic but mainly is made up by several kinds of effective ingredients of biological substances refined from various natural herbs and bioproducts. Drug addicts can be weaned and cured safely from addiction induced by Heroin, Cocaine, Morphine, Amphetamines, Hemp or Opium, and other substances within 7-30 days, by means of DTS (Deities) which can get rid of drug poisons present in an addict's blood and marrow. Further, DTS (Deities) can also be used to clear away tobacco tar and nicotine deposits so that it serves to wean from cigarette smoking as well.Type: GrantFiled: January 8, 1991Date of Patent: March 30, 1993Inventor: Liu C. Wen